Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
29 avr. 2020 08h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
09 mars 2020 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
LSU Chemical Engineering Professor Receives NSF CAREER Award for Particle Transport Research
11 févr. 2020 13h00 HE
|
LSU College of Engineering
BATON ROUGE, La., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Assistant Professor of Chemical Engineering Bhuvnesh Barti has been awarded the National Science Foundation’s CAREER Award for his research,...
Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes
20 janv. 2020 11h32 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced that a new landmark...
Vivos Inc. Provides 2019 Recap and Outlines 2020 Objectives
13 janv. 2020 07h30 HE
|
Vivos Inc.
Richland WA, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2019 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2020, I think it is...
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
04 juin 2019 08h00 HE
|
VBI Vaccines, Inc.
Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...
Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay to Accelerate Translational and Clinical Cancer Research
29 mai 2019 08h45 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology
29 mai 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
In-Vitro Colorectal Cancer Screening Tests Market worth $1.3Bn by 2025: Global Market Insights, Inc.
13 mars 2019 05h00 HE
|
Global Market Insights, Inc
Sellbyville, Delaware, March 13, 2019 (GLOBE NEWSWIRE) -- Germany in-vitro colorectal cancer screening tests market is projected to witness robust business growth in foreseeable future with...
Admera Health Expands Liquid Biopsy Offering to Include Detection of Copy Number Variation and Microsatellite Instability
23 oct. 2018 09h13 HE
|
Admera Health, LLC
SOUTH PLAINFIELD, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- At CAP18, in Chicago, IL, Admera Health (www.admerahealth.com), unveiled an expansion to its next generation sequencing (NGS) based...